(NASDAQ: RXST) Rxsight's forecast annual revenue growth rate of 6.52% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.61%.
Rxsight's revenue in 2026 is $127,478,000.On average, 11 Wall Street analysts forecast RXST's revenue for 2026 to be $5,454,831,168, with the lowest RXST revenue forecast at $5,176,645,955, and the highest RXST revenue forecast at $5,698,657,195. On average, 11 Wall Street analysts forecast RXST's revenue for 2027 to be $6,003,336,237, with the lowest RXST revenue forecast at $5,513,200,387, and the highest RXST revenue forecast at $6,533,212,832.
In 2028, RXST is forecast to generate $6,495,541,918 in revenue, with the lowest revenue forecast at $5,801,320,785 and the highest revenue forecast at $7,106,969,833.